Solidion Chairman and CEO Jaymes Winters said the new DOE award highlights the strength of the company’s innovation and IP portfolio work. [Image: DI Studio composite; Credits: Zarina Lukash/istockphoto, Nasdaq Exchange footage, and Solidion]
Alphabet spinoff Verily Life Sciences, based in Dallas, has received a patent for a method that uses artificial intelligence to predict prostate cancer outcomes. The approach involves applying an AI Gleason grading model to prostate tissue images, determining the relative proportions of Gleason patterns, and generating an automated risk score or risk group value. Figure 4 from the patent illustrates how an AI-generated risk group score could be presented on a clinician’s workstation. [Composite illustration: Sources, USPTO Patent #12444044, Fig. 4; DI Studio]